10.16
-0.29
(-2.78%)
As of 10:32:23 AM EDT. Market Open.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
611,562
611,562
482,262
350,867
243,212
Cost of Revenue
187,300
187,300
172,059
117,808
85,450
Gross Profit
424,262
424,262
310,203
233,059
157,762
Operating Expense
547,175
547,175
458,479
354,161
266,634
Operating Income
-122,913
-122,913
-148,276
-121,102
-108,872
Net Non Operating Interest Income Expense
-24,879
-24,879
-16,641
-5,505
-7,108
Other Income Expense
-14,281
-14,281
-21,998
-25,402
-28,182
Pretax Income
-162,073
-162,073
-186,915
-152,009
-144,162
Tax Provision
50
50
-277
-716
-1,130
Net Income Common Stockholders
-162,123
-162,123
-186,638
-151,293
-143,032
Diluted NI Available to Com Stockholders
-162,123
-162,123
-186,638
-151,293
-143,032
Basic EPS
-1.13
--
-1.54
-1.47
-1.50
Diluted EPS
-1.13
--
-1.54
-1.47
-1.50
Basic Average Shares
142,946
--
121,242
103,373
96,197
Diluted Average Shares
142,946
--
121,242
103,373
96,197
Total Operating Income as Reported
-136,169
-136,169
-173,395
-146,975
-128,057
Total Expenses
734,475
734,475
630,538
471,969
352,084
Net Income from Continuing & Discontinued Operation
-162,123
-162,123
-186,638
-151,293
-143,032
Normalized Income
-151,650.76
-151,650.76
-161,561.70
-125,541.60
-116,623.29
Interest Expense
24,879
24,879
16,641
5,505
7,108
Net Interest Income
-24,879
-24,879
-16,641
-5,505
-7,108
EBIT
-137,194
-137,194
-170,274
-146,504
-137,054
EBITDA
-53,874
-53,874
-110,592
-102,576
-106,880
Reconciled Cost of Revenue
120,238
120,238
126,661
83,995
60,624
Reconciled Depreciation
83,320
83,320
59,682
43,928
30,174
Net Income from Continuing Operation Net Minority Interest
-162,123
-162,123
-186,638
-151,293
-143,032
Total Unusual Items Excluding Goodwill
-13,256
-13,256
-25,119
-25,873
-26,619
Total Unusual Items
-13,256
-13,256
-25,119
-25,873
-26,619
Normalized EBITDA
-40,618
-40,618
-85,473
-76,703
-80,261
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-2,783.76
-2,783.76
-42.70
-121.60
-210.29
12/31/2021 - 6/12/2006
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
OFIX Orthofix Medical Inc.
15.77
-3.25%
FNA Paragon 28, Inc.
13.06
-0.15%
LUNG Pulmonx Corporation
6.66
-2.35%
GMED Globus Medical, Inc.
73.21
-3.03%
BVS Bioventus Inc.
8.96
-5.78%
SIBN SI-BONE, Inc.
13.52
-5.85%
KIDS OrthoPediatrics Corp.
25.36
-3.63%
ZIMV ZimVie Inc.
10.13
-4.07%
TLSI TriSalus Life Sciences, Inc.
5.47
-1.09%
LIVN LivaNova PLC
37.50
-5.08%